

Douglas A Levine

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7678517/douglas-a-levine-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160
papers

21,616
citations

62
h-index

146
g-index

174
ext. papers

28,389
ext. citations

10.1
avg, IF

6.09
L-index

#	Paper	IF	Citations
160	A perception-based nanosensor platform to detect cancer biomarkers. <i>Science Advances</i> , 2021 , 7, eabj08523	17.3	10
159	Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. <i>Gynecologic Oncology</i> , 2021 , 161, 113-121	4.9	16
158	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021 , 127, 2409-2422	6.4	14
157	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. <i>Carcinogenesis</i> , 2021 , 42, 785-793	4.6	1
156	Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	4
155	Population-based targeted sequencing of 54 candidate genes identifies a susceptibility gene for high-grade serous ovarian cancer. <i>Journal of Medical Genetics</i> , 2021 , 58, 305-313	5.8	12
154	Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. <i>Cancer Discovery</i> , 2021 , 11, 362-383	24.4	15
153	Uterine carcinosarcomas: From pathology to practice. <i>Gynecologic Oncology</i> , 2021 , 162, 235-241	4.9	3
152	Endometrial cancer. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 88	51.1	13
151	Proteogenomic Characterization of Endometrial Carcinoma. <i>Cell</i> , 2020 , 180, 729-748.e26	56.2	122
150	Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression. <i>Gynecologic Oncology</i> , 2020 , 157, 280-286	4.9	2
149	Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. <i>Cell</i> , 2020 , 183, 1436-1456.e31	46.7	31
148	Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma. <i>Cell Reports</i> , 2020 , 33, 108276	10.6	33
147	Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines. <i>Clinical Cancer Research</i> , 2020 , 26, 3908-3917	12.9	28
146	Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. <i>Nature Communications</i> , 2019 , 10, 4369	17.4	8
145	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019 , 10, 431	17.4	45
144	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. <i>Nature Communications</i> , 2019 , 10, 558	17.4	42

143	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , 2019 , 8, 2503-2513	4.8	4
142	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019 , 125, 1963-1972	6.4	22
141	Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility. <i>Gynecologic Oncology</i> , 2019 , 155, 473-482	4.9	3
140	Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. <i>Nature Communications</i> , 2019 , 10, 5367	17.4	79
139	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019 , 79, 505-517	10.1	28
138	Small cell cancers of the female genital tract: Molecular and clinical aspects. <i>Gynecologic Oncology</i> , 2018 , 149, 420-427	4.9	28
137	Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. <i>American Journal of Surgical Pathology</i> , 2018 , 42, 561-568	6.7	117
136	Noninvasive ovarian cancer biomarker detection via an optical nanosensor implant. <i>Science Advances</i> , 2018 , 4, eaaq1090	14.3	78
135	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018 , 118, 1123-1129	8.7	10
134	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. <i>Cell</i> , 2018 , 173, 400-416.e11	56.2	1072
133	Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 787-790	9.7	82
132	Racial disparities in molecular subtypes of endometrial cancer. <i>Gynecologic Oncology</i> , 2018 , 149, 106-116	4.9	25
131	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018 , 33, 690-705.e9	24.3	277
130	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	110
129	A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2018 , 149, 585-591	4.9	38
128	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018 , 78, 5419-5430	10.1	32
127	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018 , 13, e0197561	3.7	9
126	Missed opportunities: Genetic counseling and testing among an ethnically diverse cohort of women with endometrial cancer. <i>Gynecologic Oncology</i> , 2018 , 151, 153-158	4.9	13

125	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	3
124	Genomic mutation profiles of paired ovarian cancers (OC) across time.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5521-5521	2.2	1
123	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. <i>Cancer Prevention Research</i> , 2018 , 11, 697-706	3.2	33
122	A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2018 , 150, 274-281	4.9	67
121	A pair of datasets for microRNA expression profiling to examine the use of careful study design for assigning arrays to samples. <i>Scientific Data</i> , 2018 , 5, 180084	8.2	1
120	Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. <i>Gynecologic Oncology</i> , 2018 , 150, 127-135	4.9	33
119	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. <i>British Journal of Cancer</i> , 2017 , 116, 524-535	8.7	18
118	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. <i>Gynecologic Oncology</i> , 2017 , 145, 15-20	4.9	44
117	Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. <i>Cancer</i> , 2017 , 123, 3261-3268	6.4	52
116	Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. <i>ACS Chemical Biology</i> , 2017 , 12, 2085-2096	4.9	20
115	miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. <i>Scientific Reports</i> , 2017 , 7, 3614	4.9	18
114	Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. <i>Gynecologic Oncology</i> , 2017 , 146, 101-108	4.9	24
113	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691	36.3	190
112	A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. <i>European Radiology</i> , 2017 , 27, 3991-4001	8	65
111	Integrated Molecular Characterization of Uterine Carcinosarcoma. <i>Cancer Cell</i> , 2017 , 31, 411-423	24.3	210
110	Genetic predisposition to bevacizumab-induced hypertension. <i>Gynecologic Oncology</i> , 2017 , 147, 621-625	4.9	13
109	Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. <i>Nature Communications</i> , 2017 , 8, 990	17.4	109
108	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	699

107	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. <i>Nature Communications</i> , 2017 , 8, 310	17.4	112
106	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 420-424	4	3
105	The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair. <i>Oncotarget</i> , 2017 , 8, 13792-13804	3.3	9
104	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. <i>Oncotarget</i> , 2017 , 8, 84579-84594	3.3	18
103	Genetics in the development of endometrial cancer: How does it affect East Asians?. <i>Journal of Clinical Oncology</i> , 2017 , 35, e13022-e13022	2.2	
102	Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. <i>Annals of Surgical Oncology</i> , 2016 , 23, 196-202	3.1	63
101	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016 , 141, 386-401	4.9	15
100	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016 , 6, 1052-67	24.4	104
99	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016 , 7, 12675	17.4	53
98	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. <i>Cancer Prevention Research</i> , 2016 , 9, 713-20	3.2	6
97	Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures. <i>Journal of Proteome Research</i> , 2016 , 15, 2455-65	5.6	28
96	Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. <i>International Journal of Gynecological Pathology</i> , 2016 , 35, 48-55	3.2	110
95	Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. <i>Gynecologic Oncology</i> , 2016 , 142, 217-24	4.9	29
94	Study design and data analysis considerations for the discovery of prognostic molecular biomarkers: a case study of progression free survival in advanced serous ovarian cancer. <i>BMC Medical Genomics</i> , 2016 , 9, 27	3.7	6
93	Uterine adenosarcomas are mesenchymal neoplasms. <i>Journal of Pathology</i> , 2016 , 238, 381-8	9.4	70
92	Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. <i>Cell</i> , 2016 , 166, 755-765	56.2	544
91	Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016 , 140, 436-42	4.9	75
90	Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 2192-8	3.1	31

89	Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. <i>Cell Reports</i> , 2016 , 14, 429-439	10.6	91
88	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 446-54	4	6
87	Is It Time to Centralize Ovarian Cancer Care in the United States?. <i>Annals of Surgical Oncology</i> , 2016 , 23, 989-93	3.1	29
86	Evidence of a genetic link between endometriosis and ovarian cancer. <i>Fertility and Sterility</i> , 2016 , 105, 35-43.e1-10	4.8	26
85	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 69097-69110	3.3	4
84	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016 , 7, 72381-72394	3.3	11
83	A targeted genetic association study of epithelial ovarian cancer susceptibility. <i>Oncotarget</i> , 2016 , 7, 7381-9	3.9	7
82	The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility. <i>International Journal of Gynecological Pathology</i> , 2016 , 35, 16-24	3.2	28
81	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016 , 45, 884-95	7.8	45
80	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. <i>JAMA Oncology</i> , 2016 , 2, 1434-1440	13.4	151
79	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. <i>Human Molecular Genetics</i> , 2016 , 25, 3600-3612	5.6	9
78	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016 , 53, 800-811	5.8	121
77	Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type. <i>Modern Pathology</i> , 2016 , 29, 60-6	9.8	49
76	The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. <i>Gynecologic Oncology</i> , 2016 , 141, 454-460	4.9	61
75	Evolving Approaches in Research and Care for Ovarian Cancers: A Report From the National Academies of Sciences, Engineering, and Medicine. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1943-4	27.4	7
74	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016 , 135, 741-56	6.3	18
73	Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery. <i>Annals of Surgical Oncology</i> , 2016 , 23, 2522-8	3.1	47
72	Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016 , 141, 260-263	4.9	53

71	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016 , 45, 1619-1630	7.8	77
70	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015 , 47, 164-71	36.3	177
69	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1574-84	4	24
68	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015 , 21, 5264-76	12.9	24
67	Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. <i>JAMA Oncology</i> , 2015 , 1, 486-94	13.4	27
66	Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. <i>Gynecologic Oncology</i> , 2015 , 136, 542-8	4.9	12
65	Phosphotyrosine signaling analysis in human tumors is confounded by systemic ischemia-driven artifacts and intra-specimen heterogeneity. <i>Cancer Research</i> , 2015 , 75, 1495-503	10.1	35
64	Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome. <i>Neoplasia</i> , 2015 , 17, 183-9	6.4	27
63	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015 , 6, 8234	17.4	40
62	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015 , 36, 1341-53	4.6	20
61	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015 , 15, 668-79	31.3	581
60	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015 , 24, 5955-64	5.6	48
59	Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015 , 138, 246-51	4.9	53
58	UNDO: a Bioconductor R package for unsupervised deconvolution of mixed gene expressions in tumor samples. <i>Bioinformatics</i> , 2015 , 31, 137-9	7.2	42
57	Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes. <i>Journal of Proteome Research</i> , 2015 , 14, 422-33	5.6	24
56	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. <i>Modern Pathology</i> , 2015 , 28, 505-14	9.8	136
55	Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma. <i>Cancer Cytopathology</i> , 2015 , 123, 289-97	3.9	21
54	BACOM2.0 facilitates absolute normalization and quantification of somatic copy number alterations in heterogeneous tumor. <i>Scientific Reports</i> , 2015 , 5, 13955	4.9	5

53	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015 , 39, 689-97	2.6	18
52	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015 , 10, e0128106	3.7	15
51	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2015 , 24, 3595-607	5.6	32
50	Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. <i>PLoS ONE</i> , 2015 , 10, e0126633	3.7	27
49	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015 , 2,		22
48	Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	124
47	DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. <i>Autophagy</i> , 2014 , 10, 1071-92	10.2	46
46	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. <i>Molecular and Cellular Proteomics</i> , 2014 , 13, 1690-704	7.6	239
45	A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. <i>Gynecologic Oncology</i> , 2014 , 134, 455-61	4.9	134
44	New insights into PARP inhibitors effect on cell cycle and homology-directed DNA damage repair. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 1645-54	6.1	54
43	Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency. <i>Modern Pathology</i> , 2014 , 27, 1405-11	9.8	30
42	Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2014 , 135, 49-53	4.9	20
41	Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. <i>Nature Genetics</i> , 2014 , 46, 424-6	36.3	231
40	Blocking and randomization to improve molecular biomarker discovery. <i>Clinical Cancer Research</i> , 2014 , 20, 3371-8	12.9	12
39	Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. <i>Gynecologic Oncology</i> , 2014 , 133, 274-7	4.9	201
38	Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2014 , 132, 299-302	4.9	8
37	Evaluating cell lines as tumour models by comparison of genomic profiles. <i>Nature Communications</i> , 2013 , 4, 2126	17.4	831
36	Inferring tumour purity and stromal and immune cell admixture from expression data. <i>Nature Communications</i> , 2013 , 4, 2612	17.4	2572

35	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2	36.3	422
34	Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2013 , 128, 512-7	4.9	34
33	Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. <i>Science Translational Medicine</i> , 2013 , 5, 167ra4	17.5	208
32	Integrated genomic characterization of endometrial carcinoma. <i>Nature</i> , 2013 , 497, 67-73	50.4	2800
31	BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. <i>Cancer</i> , 2013 , 119, 548-554	6.4	135
30	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013 , 4, 1627	17.4	85
29	BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 138-46	6.7	47
28	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. <i>Journal of Clinical Investigation</i> , 2013 , 123, 517-25	15.9	371
27	An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). <i>Gynecologic Oncology</i> , 2012 , 124, 10-4	4.9	199
26	Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1503-13	9.7	191
25	Absolute quantification of somatic DNA alterations in human cancer. <i>Nature Biotechnology</i> , 2012 , 30, 413-21	44.5	1229
24	Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. <i>International Journal of Gynecological Pathology</i> , 2012 , 31, 48-56	3.2	58
23	Genomic complexity and AKT dependence in serous ovarian cancer. <i>Cancer Discovery</i> , 2012 , 2, 56-67	24.4	89
22	Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. <i>Modern Pathology</i> , 2012 , 25, 625-36	9.8	150
21	Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma. <i>American Journal of Surgical Pathology</i> , 2012 , 36, 1771-81	6.7	21
20	Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. <i>PLoS ONE</i> , 2011 , 6, e24709	3.7	72
19	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011 , 11, 719-25	31.3	893
18	Common variants at 19p13 are associated with susceptibility to ovarian cancer. <i>Nature Genetics</i> , 2010 , 42, 880-4	36.3	210

17	Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3555-61	2.2	371
16	A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. <i>American Journal of Pathology</i> , 2010 , 177, 908-17	5.8	62
15	Genomic and biological characterization of exon 4 KRAS mutations in human cancer. <i>Cancer Research</i> , 2010 , 70, 5901-11	10.1	218
14	Genetic analysis of the early natural history of epithelial ovarian carcinoma. <i>PLoS ONE</i> , 2010 , 5, e10358	3.7	74
13	Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. <i>Clinical Cancer Research</i> , 2009 , 15, 2448-55	12.9	55
12	A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. <i>Cancer Research</i> , 2008 , 68, 5478-86	10.1	301
11	Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. <i>Annals of Surgical Oncology</i> , 2007 , 14, 2510-8	3.1	72
10	Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1745-53	2.2	129
9	Frequent mutation of the PIK3CA gene in ovarian and breast cancers. <i>Clinical Cancer Research</i> , 2005 , 11, 2875-8	12.9	347
8	Gene expression signature with independent prognostic significance in epithelial ovarian cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4700-10	2.2	217
7	Gastrointestinal adenocarcinoma arising in a mature cystic teratoma of the ovary. <i>Gynecologic Oncology</i> , 2004 , 94, 597-9	4.9	22
6	Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4222-7	2.2	169
5	Prophylactic surgery in hereditary breast/ovarian cancer syndrome. <i>Oncology</i> , 2003 , 17, 932-41; discussion 946-8, 950-2	1.8	4
4	Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. <i>Gynecologic Oncology</i> , 2002 , 85, 431-4	4.9	34
3	Update in the management of endometrial cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2002 , 8 Suppl 1, S31-40		3
2	Risk of endometrial carcinoma associated with BRCA mutation. <i>Gynecologic Oncology</i> , 2001 , 80, 395-8	4.9	135
1	Both Fallopian Tube and Ovarian Surface Epithelium Can Act as Cell-of-Origin for High Grade Serous Ovarian Carcinoma		2